GenScript ProBio Congratulates Selecxine’s IND Clearance from MFDS

Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp

A bispecific antibody molecule jointly developed by Buchang Pharmaceutical and REMD Biotherapeutics，partners of GenScript ProBio, received IND clearance from NMPA for clinical trial

GenScript ProBio Licenses Novel Fc Silencing Technology from mAbsolve

GenScript ProBio Enters Strategic Collaboration with Hibiocy Co. Ltd, the affiliate of Rojukiss International Public Company Limited (KISS) – the leading Thai-based Beauty & Health company, for the development and manufacturing of COVITRAP™ and future new

GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft To Development and Production of New AAV gene therapies

GenScript ProBio Congratulates Selecxine on FDA Clearance of IND Application for Innovative Antibody Drug Program

GenScript ProBio and DAAN Bio Therapeutics, Sign a Strategic Cooperation MOU for the Discovery and Development of Novel Drugs

GenScript ProBio Signs MOU to Form Strategic Partnership with ACT Therapeutics to Development of New CAR-T Cell Therapies

GenScript ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System

Athenex Partners with Leading Contract Manufacturer GenScript ProBio in the Development of Advanced Cell and Gene Therapies

GenScript ProBio Signs CDMO Supply Agreement And Forms Strategic Partnership with AffyXell Therapeutics – A Joint Daewong-Avacta Venture

National Cancer Center Japan and GenScript ProBio Enter Research Collaboration Agreement for a Plasmid & Lentiviral vector CMC development

GenScript ProBio initiates an Antibody CDMO contract for next-generation CD47 antibody with InnoBation Bio

Successful Groundbreaking Ceremony for GenScript ProBio to Expand Commercial cGMP Plasmid and Viral Vector Manufacturing Facility in Zhenjiang, China

GenScript ProBio and AbTis Enter into an Exclusive Worldwide License Agreement for ADC Targeting Claudin 18.2

China’s Largest Commercial GMP Plasmid Manufacturing Facility is Put into Operation, GenScript ProBio Expanding Manufacturing Capacity Again

GenScript ProBio Named a Top 10 Drug Discovery Solution Provider in Asia-Pacific

GenScript ProBio Passed European Union Qualified Person (QP) Audit Successfully

GenScript ProBio Congratulates EyeGene for Clinical Trial Approval for mRNA COVID-19 Vaccine in South Korea